How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

National security, unlocked. Each Thursday, host Mary Louise Kelly and a team of NPR correspondents discuss the biggest national security news of the week. With decades of reporting from battlefields ...

This Perspective examines the role of AI-based image analysis when applied to stem cell-derived models. We developed an optogenetic tool based on tetanus neurotoxin — a protease that cleaves the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Find out the direct holders, institutional holders and mutual fund holders for Recursion Pharmaceuticals, Inc. (RXRX).